Anti-cancer nuclear hormone receptor-targeting compounds
US11834458B2 · kind B2 · utility
0Cited by
21References
34Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 22, 2022 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Mar 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J73/008
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.